C-Peptide as an Endpoint in Clinical Trials: Its Time Has Come
A new publication provides more evidence for C-peptide as a validated surrogate to predict clinical benefits of disease-modifying therapies in…
A New Shot on Goal for Cell Therapies In T1D
Eledon Pharmaceuticals announces new funding from the T1D Fund and the launch of their clinical trial for tegoprubart in T1D.
The Kelley Family: Enduring to Cure T1D
The Kelley family is involved with our organization in every way possible. But for Margaret Kelley, our endurance event is…
School nurses have incredible impact
School nurses are essential to a child’s type 1 diabetes (T1D) care.
The Merwin Family: Aiming for the Ultimate Finish Line
The Merwin Family found their purpose with our organization after their child was diagnosed with T1D.
Meet Our New International Board of Directors Vice Chair, Matt Varey
Matt Varey, the newly elected Vice Chair of the Breakthrough T1D International Board of Directors (IBOD), brings a truly global…
Beating the Odds: The Improbable Story of How Perseverance, Belief, and Luck Led to the Approval of the First Life-Changing Immune Therapy for Type 1 Diabetes
The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D)…
Breakthrough T1D One Walk Goes Virtual in Roblox
The new Charity Walk Simulator in Breakthrough T1D One World on Roblox puts players in charge of their very own…
Walk Across Generations
Breakthrough T1D One Walk is more than a fundraiser, it’s a community. Meet two Walk team members who found support…
Meet Our New International Board of Directors Chair, Lisa F. Wallack
Lisa F. Wallack, newly elected Chair of the Breakthrough T1D International Board of Directors, is carrying on her family's legacy…
